Using a new treatment to reduce organ damage after severe blood loss
Recombinant E-NTPDase for shock
This study is testing a new treatment that uses a special enzyme to help protect your body from damage after losing a lot of blood and getting it back quickly, which can happen in emergencies; it aims to see if combining this treatment with IV fluids can reduce inflammation and organ injury, and it could be helpful for patients like you who have experienced severe blood loss.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Purine Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Gillette, United States) |
| Project ID | NIH-10757117 on NIH RePORTER |
What this research studies
This research investigates a novel treatment using a recombinant enzyme called E-NTPDase to help protect the body from damage caused by low blood volume and subsequent restoration of blood flow, known as hemorrhagic shock. The study aims to assess how this treatment can be combined with intravenous fluids to minimize inflammation and organ injury that often occurs after such traumatic events. By conducting a dose-escalation study, researchers will evaluate the effectiveness of this new therapy in preventing complications associated with ischemia-reperfusion injury. Patients experiencing severe blood loss may benefit from this innovative approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced severe blood loss due to trauma or other medical emergencies.
Not a fit: Patients who are not experiencing hemorrhagic shock or those with conditions unrelated to blood loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce organ damage and improve recovery outcomes for patients suffering from hemorrhagic shock.
How similar studies have performed: Previous research has shown promise in using E-NTPDases to mitigate organ injury in animal models, suggesting potential for success in human applications.
Where this research is happening
Gillette, United States
- Purine Pharmaceuticals, INC. — Gillette, United States (Active)
Researchers
- Principal investigator: Hasko, George — Purine Pharmaceuticals, INC.
- Study coordinator: Hasko, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.